ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Sari H. Enschede et al.|Nature Medicine|2013Cited by 3k
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J. Faivre, Yu Shen, Keith F. McDaniel et al.|Nature|2020Cited by 404
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> ActivityZhi‐Fu Tao, Andrew J. Souers, Lisa Hasvold et al.|ACS Medicinal Chemistry Letters|2014Cited by 331
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182